Abarelix
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Ceritinib
Tyrosine Kinase Inhibitor · Antineoplastic
Tyrosine Kinase InhibitorAntineoplasticATC null
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
X
FDA category + note
Top interactionssee all 12 →
- AbarelixSevereDatabaseDDInter
- AbemaciclibSevereDatabaseDDInter
- AbirateroneSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
Mechanism
Ceritinib is a tyrosine kinase inhibitor, with particular activity against anaplastic lymphoma kinase (ALK).
Indications
First-line treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (specialist use only)Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer previously treated with crizotinib (specialist use only)lung NSCLC (ALK translocation)ALK-positive metastatic NSCLC unresponsive to crizotinib
Dosing
- Adult
- 450 mg once daily, dose interruption, dose reduction or discontinuation may be required based on individual safety and tolerability—consult product literature; discontinue treatment if patient unable to tolerate at least 150 mg daily. If concurrent use of potent inhibitors of CYP3A4 is unavoidable, reduce the dose by one-third (rounded to the nearest multiple of the 150 mg dosage form).
Pharmacokinetics
Half-life
41 h
Metabolism
CYP3A
Contraindications
- Congenital long QT syndrome
- Diabetes mellitus . history or susceptibility to QT-interval prolongation
Side effects
Common
GI toxicityhepatotoxicity
Serious
- QT-interval prolongation, which may lead to ventricular tachyarrhythmias (e.g., torsade de pointes) or sudden death
- bradycardia
- prolonged QT intervals
Pregnancy & lactation
Pregnancy
X
Drug interactions
Abemaciclib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Abiraterone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Acalabrutinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Acebutolol
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adenosine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alfentanil
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Alfuzosin
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Alimemazine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amiodarone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amisulpride
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amitriptyline
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Other Tyrosine Kinase Inhibitor drugs
Ask House about Ceritinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team